AI assistant
POLAREAN IMAGING PLC — Capital/Financing Update 2019
Sep 25, 2019
7850_rns_2019-09-25_d8e26d4f-7219-4b8f-8422-51a3945202c6.html
Capital/Financing Update
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 5457N
Polarean Imaging PLC
25 September 2019
Polarean Imaging Plc
("Polarean" or the "Company")
Polarean notes statement from Amphion Innovations
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made by its partner company, Amphion Innovations Plc ("Amphion") that Amphion has agreed to amend the terms of the Loan Facility with Amphion's debt provider ("the Lender").
The Lender has agreed to extend the maturity date of the Loan Facility to 30 September 2020. No other terms have been amended.
The loan amount under the Facility will continue to be secured by the Amphion's pledge of 16,722,523 ordinary shares of Polarean. Amphion has transferred the legal title of the total pledged shares in Polarean to the Lender, but retains the beneficial interest in the shares.
Amphion holds 16,722,523 ordinary shares of Polarean, representing 14.61% of the issued share capital.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
Enquiries:
| Polarean Imaging plc | www.polarean.com / www.polarean-ir.com | |||
| Richard Hullihen, Chief Executive Officer | Via Walbrook PR | |||
| Richard Morgan, Chairman | ||||
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 | |||
| David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance) | ||||
| Vadim Alexandre / Rob Rees (Corporate Broking) | ||||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | |||
| Anna Dunphy / Paul McManus | Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 | |||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
MSCEAANLAALNEAF